Ratios in Focus: Analyzing Crinetics Pharmaceuticals Inc (CRNX)’s Price-to-Cash and Price-to-Free Cash Flow

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $50.70 down -1.93% from its previous closing price of $51.70. In other words, the price has decreased by -$1.93 from its previous closing price. On the day, 2.53 million shares were traded. CRNX stock price reached its highest trading level at $52.675 during the session, while it also had its lowest trading level at $49.51.

Ratios:

For a deeper understanding of Crinetics Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.09 and its Current Ratio is at 16.09. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 06, 2024, initiated with a Buy rating and assigned the stock a target price of $68.

On January 16, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $50.

On December 21, 2023, Jefferies started tracking the stock assigning a Hold rating and target price of $35.Jefferies initiated its Hold rating on December 21, 2023, with a $35 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 03 ’24 when Pizzuti Dana sold 14,375 shares for $54.63 per share. The transaction valued at 785,306 led to the insider holds 28,507 shares of the business.

DANA J PIZZUTI bought 14,375 shares of CRNX for $785,322 on Oct 03 ’24. On Sep 26 ’24, another insider, Wilson Marc, who serves as the CFO of the company, sold 25,000 shares for $51.11 each. As a result, the insider received 1,277,750 and left with 111,092 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 4057805056 and an Enterprise Value of 3248170496. Its current Enterprise Value per Revenue stands at 2345.249 whereas that against EBITDA is -11.761.

Stock Price History:

Over the past 52 weeks, CRNX has reached a high of $55.78, while it has fallen to a 52-week low of $25.75. The 50-Day Moving Average of the stock is -2.19%, while the 200-Day Moving Average is calculated to be 10.91%.

Shares Statistics:

For the past three months, CRNX has traded an average of 627.63K shares per day and 715450 over the past ten days. A total of 80.04M shares are outstanding, with a floating share count of 75.22M. Insiders hold about 6.01% of the company’s shares, while institutions hold 100.51% stake in the company. Shares short for CRNX as of 1726185600 were 6113544 with a Short Ratio of 9.74, compared to 1723680000 on 6470497. Therefore, it implies a Short% of Shares Outstanding of 6113544 and a Short% of Float of 7.8.

Most Popular